MindMed’s Phase 2b LSD (MM120) for generalised anxiety disorder (GAD) study, published in JAMA earlier this month, shows promising efficacy and a favourable safety profile. Here, we speak to researchers about the trial, diving deeper into topics including the dose-response effect, the candidate’s safety profile, and non-pharmacological elements of the study, including the company’s decision not to record any of the sessions in its Phase 2b or Phase 3 studies.
